Barely Significant
← all excerpts

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.

Cancer Med · 2023 · PMC10278531 · PMID 37096765

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendp = 0.05actually significant
More exposure to cytotoxic chemotherapy before osimertinib showed a trend toward systemic PD (20.0% vs. 37.9%, p = 0.05, Table 2 ).

also in 33,481 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.